BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

183 related articles for article (PubMed ID: 37052701)

  • 41. KHYG-1, a model for the study of enhanced natural killer cell cytotoxicity.
    Suck G; Branch DR; Smyth MJ; Miller RG; Vergidis J; Fahim S; Keating A
    Exp Hematol; 2005 Oct; 33(10):1160-71. PubMed ID: 16219538
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Recent advances in chimeric antigen receptor natural killer cell therapy for overcoming intractable hematological malignancies.
    Tanaka J
    Hematol Oncol; 2021 Feb; 39(1):11-19. PubMed ID: 32905618
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Effector cells derived from host CD8 memory T cells mediate rapid resistance against minor histocompatibility antigen-mismatched allogeneic marrow grafts without participation of perforin, Fas ligand, and the simultaneous inhibition of 3 tumor necrosis factor family effector pathways.
    Zimmerman Z; Shatry A; Deyev V; Podack E; Mammolenti M; Blazar BR; Yagita H; Levy RB
    Biol Blood Marrow Transplant; 2005 Aug; 11(8):576-86. PubMed ID: 16041307
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Expression of FasL and perforin/granzyme B mRNA in chronic hepatitis B virus infection.
    Lee JY; Chae DW; Kim SM; Nam ES; Jang MK; Lee JH; Kim HY; Yoo JY
    J Viral Hepat; 2004 Mar; 11(2):130-5. PubMed ID: 14996347
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Impact of FASL-induced apoptosis in the elimination of tumor cells by NK cells.
    Screpanti V; Wallin RP; Grandien A; Ljunggren HG
    Mol Immunol; 2005 Feb; 42(4):495-9. PubMed ID: 15607805
    [TBL] [Abstract][Full Text] [Related]  

  • 46. An NK cell line (NK92-41BB) expressing high levels of granzyme is engineered to express the high affinity chimeric genes CD16/CAR.
    Zhao H; Zhou Z; Li G; Liu G; Lin S; Chen W; Xiong S
    Cytotechnology; 2021 Aug; 73(4):539-553. PubMed ID: 34349345
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Targeting FLT3-specific chimeric antigen receptor T cells for acute lymphoblastic leukemia with KMT2A rearrangement.
    Suematsu M; Yagyu S; Yoshida H; Osone S; Nakazawa Y; Sugita K; Imamura T; Iehara T
    Cancer Immunol Immunother; 2023 Apr; 72(4):957-968. PubMed ID: 36214866
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Combination Therapy with EpCAM-CAR-NK-92 Cells and Regorafenib against Human Colorectal Cancer Models.
    Zhang Q; Zhang H; Ding J; Liu H; Li H; Li H; Lu M; Miao Y; Li L; Zheng J
    J Immunol Res; 2018; 2018():4263520. PubMed ID: 30410941
    [TBL] [Abstract][Full Text] [Related]  

  • 49. IFNalpha2b stimulated release of IFNgamma differentially regulates T cell and NK cell mediated tumor cell cytotoxicity.
    Bose A; Baral R
    Immunol Lett; 2007 Jan; 108(1):68-77. PubMed ID: 17112599
    [TBL] [Abstract][Full Text] [Related]  

  • 50. High-free Fatty Acid Treatment Induced Anti-inflammatory Changes in a Natural Killer (NK) Cell Line.
    Wu H; Fu Y; Jiang Y; Liu Y; Cheng Z; Shao Y; Nie Y
    Iran J Immunol; 2023 Dec; 20(4):456-465. PubMed ID: 37865874
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Perforin-independent CD8(+) T-cell-mediated cytotoxicity of alveolar epithelial cells is preferentially mediated by tumor necrosis factor-alpha: relative insensitivity to Fas ligand.
    Liu AN; Mohammed AZ; Rice WR; Fiedeldey DT; Liebermann JS; Whitsett JA; Braciale TJ; Enelow RI
    Am J Respir Cell Mol Biol; 1999 May; 20(5):849-58. PubMed ID: 10226053
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Xenogeneic human NK cytotoxicity against porcine endothelial cells is perforin/granzyme B dependent and not inhibited by Bcl-2 overexpression.
    Matter-Reissmann UB; Forte P; Schneider MK; Filgueira L; Groscurth P; Seebach JD
    Xenotransplantation; 2002 Sep; 9(5):325-37. PubMed ID: 12199864
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Serpin B9 controls tumor cell killing by CAR T cells.
    Kimman T; Slomp A; Martens A; Grabherr S; Li S; van Diest E; Meeldijk J; Kuball J; Minnema MC; Eldering E; Bovenschen N; Sebestyén Z; Peperzak V
    J Immunother Cancer; 2023 Mar; 11(3):. PubMed ID: 36931661
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Intrinsic Functional Potential of NK-Cell Subsets Constrains Retargeting Driven by Chimeric Antigen Receptors.
    Oei VYS; Siernicka M; Graczyk-Jarzynka A; Hoel HJ; Yang W; Palacios D; Almåsbak H; Bajor M; Clement D; Brandt L; Önfelt B; Goodridge J; Winiarska M; Zagozdzon R; Olweus J; Kyte JA; Malmberg KJ
    Cancer Immunol Res; 2018 Apr; 6(4):467-480. PubMed ID: 29459477
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Bortezomib improves adoptive carbonic anhydrase IX‑specific chimeric antigen receptor‑modified NK92 cell therapy in mouse models of human renal cell carcinoma.
    Zhang Q; Xu J; Ding J; Liu H; Li H; Li H; Lu M; Miao Y; Wang Z; Fu Q; Zheng J
    Oncol Rep; 2018 Dec; 40(6):3714-3724. PubMed ID: 30272343
    [TBL] [Abstract][Full Text] [Related]  

  • 56. CD19 chimeric antigen receptor-redirected T cells combined with epidermal growth factor receptor pathway substrate 8 peptide-derived dendritic cell vaccine in leukemia.
    Wu M; Zhang L; Zhang H; Ning J; Tu S; He Y; Li Y
    Cytotherapy; 2019 Jun; 21(6):659-670. PubMed ID: 31031152
    [TBL] [Abstract][Full Text] [Related]  

  • 57. NK cells switch from granzyme B to death receptor-mediated cytotoxicity during serial killing.
    Prager I; Liesche C; van Ooijen H; Urlaub D; Verron Q; Sandström N; Fasbender F; Claus M; Eils R; Beaudouin J; Önfelt B; Watzl C
    J Exp Med; 2019 Sep; 216(9):2113-2127. PubMed ID: 31270246
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Role of the perforin/granzyme cell death pathway in D-Gal/LPS-induced inflammatory liver injury.
    Kuhla A; Eipel C; Abshagen K; Siebert N; Menger MD; Vollmar B
    Am J Physiol Gastrointest Liver Physiol; 2009 May; 296(5):G1069-76. PubMed ID: 19264954
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Construction and functional characterization of a fully human anti-CD19 chimeric antigen receptor (huCAR)-expressing primary human T cells.
    Mirzaei HR; Jamali A; Jafarzadeh L; Masoumi E; Alishah K; Fallah Mehrjardi K; Emami SAH; Noorbakhsh F; Till BG; Hadjati J
    J Cell Physiol; 2019 Jun; 234(6):9207-9215. PubMed ID: 30362586
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Receptors and lytic mediators regulating anti-tumor activity by the leukemic killer T cell line TALL-104.
    Brando C; Mukhopadhyay S; Kovacs E; Medina R; Patel P; Catina TL; Campbell KS; Santoli D
    J Leukoc Biol; 2005 Aug; 78(2):359-71. PubMed ID: 15937142
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.